Excellent sales of its Covid-19 vaccine offers a major boost to Pfizer

Since the start of the global pandemic, the attention has focused on fighting the virus through restrictive measures, pending the development of different vaccines to immunise most of the population as soon as possible. The primary aim of this was to begin to defeat the virus and gradually return back to our normal lives. Since the candidate Covid-19 vaccines were announced last November, both Pfizer, Moderna and AstraZeneca have been in the spotlight.

If, during this period, AstraZeneca has received almost all the criticism, due to distribution problems and side effects, Pfizer has been the positive face of this process. This is because, together with the Moderna formula, their vaccine has been the most requested by the different national administrations. For example, last April the European Union announced the purchase of 1.8 billion doses of Pfizer for the years 2022 and 2023.

In a recent study carried out in South Korea, it was discovered that the Pfizer vaccine showed 86.6% effectiveness in preventing the virus among those over 60 years old with only the first dose administered, which demonstrates a very positive data set.

This good news has led Pfizer to obtain exclusive results in the first quarter of 2021. As demonstrated in the results published yesterday, the company reached a profit of $4.9 billion, obtaining earnings per share of $0.93 and revenue of $14.58 billion.

These results exceeded market expectations as analysts expected Pfizer to make earnings per share of $0.77 on revenue of $13.67 billion. Despite the fact that these were better than expected and that the profit grew by 45% compared to the same period last year, yesterday there was only an increase of 0.30%.

Technically speaking, if we look at the daily chart, we can see that after marking a minimum on March 23, 2020, the price has followed an upward trend that led it to face its long-term bearish guideline after exceeding $42.80 per share which led to it making a strong correction.

Currently, the price is in a zone close to 40 dollars per share, so these positive results, together with the strength shown by the price after the triple bullish crossing in its moving averages, could lead the price to face its line against the long-term downtrend. It is important that we study the price action in the coming sessions, as the price could make a correction to its main support level at its 18-session black moving average to gain momentum. Losing this level would jeopardise this latest upward momentum.

Source: Admiral Markets MetaTrader 5. Pfizer daily chart. Data range: from August 3, 2018, to May 5, 2021. Prepared on May 5, 2021, at 12:15 CEST. Keep in mind that past returns do not guarantee future returns.

Evolution of the last 5 years:

• 2020: -0.89%
• 2019: -10.24%
• 2018: 20.51%
• 2017: 11.51%
• 2016: 0.62%

With the Admiral Markets Trade.MT5 account, you can trade Contracts for Differences (CFDs) of Pfizer and more than 3000 stocks! CFDs allow traders to try to profit from the bull and bear markets, as well as the use of leverage. Click on the following banner to open an account today:

INFORMATION ABOUT ANALYTICAL MATERIALS:

The given data provides additional information regarding all analysis, estimates, prognosis, forecasts, market reviews, weekly outlooks or other similar assessments or information (hereinafter “Analysis”) published on the websites of Admiral Markets investment firms operating under the Admiral Markets trademark (hereinafter “Admiral Markets”) Before making any investment decisions please pay close attention to the following:

1. This is a marketing communication. The content is published for informative purposes only and is in no way to be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and that it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
2. Any investment decision is made by each client alone whereas Admiral Markets shall not be responsible for any loss or damage arising from any such decision, whether or not based on the content.
3. With view to protecting the interests of our clients and the objectivity of the Analysis, Admiral Markets has established relevant internal procedures for prevention and management of conflicts of interest.
4. The Analysis is prepared by an independent analyst, Roberto Rojas (analyst), (hereinafter “Author”) based on their personal estimations.
5. Whilst every reasonable effort is taken to ensure that all sources of the content are reliable and that all information is presented, as much as possible, in an understandable, timely, precise and complete manner, Admiral Markets does not guarantee the accuracy or completeness of any information contained within the Analysis.
6. Any kind of past or modeled performance of financial instruments indicated within the content should not be construed as an express or implied promise, guarantee or implication by Admiral Markets for any future performance. The value of the financial instrument may both increase and decrease and the preservation of the asset value is not guaranteed.
7. Leveraged products (including contracts for difference) are speculative in nature and may result in losses or profit. Before you start trading, please ensure that you fully understand the risks involved.